Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of Transdermal CKR-051 in Healthy Males
NCT05833906Phase 1Completed
- Sponsor
- CK Regeon
- Start
- Apr 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of CKR-051 in wound and diabetic foot ulcer (DFU) (2 arms), sponsored by CK Regeon. Primary endpoints: Safety and tolerability (Numeric pain rating scale) - SAD at Day 1 and Safety and tolerability (Numeric pain rating scale) - MAD at Day 21. Started Apr 2023; status: completed.
02
Drugs
CKR-051
03
Conditions
wounddiabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT05833906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05833906.